Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Q4 Revenues Drop 44 Percent

NEW YORK (GenomeWeb) – Rosetta Genomics today reported a 44 percent drop in fourth quarter 2016 revenues, reflecting the absence of $1.6 million in non-recurring licensing revenue the company received in the year-ago quarter.

For the three-month period ended Dec. 31, Rosetta's revenues were $2.0 million, down from $3.6 million the year before. Revenues from clinical testing were essentially flat at $2.0 million, as declines in revenues from solid tumor and urologic cancer testing were offset by sales of the company's RosettaGX Reveal assay for the classification of indeterminate thyroid nodules and hematological FISH testing services — both of which were launched in 2016.

In recent quarters, Rosetta has been focusing its sales efforts on Reveal, which it expects will help increase demand for its other products. In the fourth quarter, sales of Reveal increased 38 percent over the third quarter to $389,000. Reveal revenues represented 19 percent of clinical testing revenues in the fourth quarter.

The firm also reported that Q4 revenues from urologic cancer testing services $1.1 million compared with $1.2 million for Q4 2015, and represented approximately 53 percent of clinical testing revenues for the quarter.  Revenues from solid tumor testing services were $404,000, compared with $726,000 for the prior year, and represented 20 percent of clinical testing revenues during the quarter. Rosetta further had $156,000 in revenues from its new Heme FISH testing business, which represented 8 percent of clinical testing revenues.

"In addition to increased unit demand for Reveal, we continue to work with payors to ensure proper payment for this assay, which we estimate has the potential to save, on average, $6,000 for each patient tested with Reveal due to its ability to prevent unnecessary thyroid surgeries," Rosetta President and CEO Kenneth Berlin said in a statement.

Rosetta's Q4 net loss narrowed to $4.8 million, or $2.73 a share, from $6.7 million, or $4.39 per share, the year before. On an adjusted basis, the company's net loss per share in the quarter was $2.32.

R&D spending in the quarter fell 18 percent to $818,000 from $1.0 million, while SG&A and business development costs declined slightly to $3.5 million from $3.6 million due to lower lower marketing and travel expenses.

For the full year 2016, Rosetta's revenues climbed nearly 10 percent to $9.2 million from $8.3 million, in part due to $854,000 in revenues from Reveal.

The company's net loss for the year narrowed to $16.2 million, or $9.31 per share, from $17.3 million, or $13.79 per share, in 2015. On an adjusted basis, the firm’s loss per share for the year was $8.50.

Full-year R&D costs were up 7 percent to $3.2 million from $3.0 million, while SG&A and business development spending declined 5 percent to $14.3 million from $15.0 million.

At the end of 2016, Rosetta had cash, cash equivalents, restricted cash, and short-term bank deposits of $6.3 million, which the company said should be sufficient to fund its operations into the third quarter of this year.

The company reiterated its 2017 revenue guidance for Reveal sales of $4 million to $5 million, with 2,500 to 3,500 tests processed throughout the year.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.